Lumeda Announces Appointment of Alexander Zinke as Chief Executive Officer
Experienced medical industry executive to lead the company in its next phase of commercialization and growth
ROCKY HILL, Conn., Oct. 16, 2020 /PRNewswire-PRWeb/ -- Lumeda Inc., a biophotonics systems company advancing photodynamic therapy (PDT) for treating cancer, today announced the appointment of Alexander (Sandy) Zinke as Chief Executive Officer. Mr. Zinke will also join the company board of directors.
As Lumeda's chief executive, Mr. Zinke will refine and implement the company strategic plan leading to commercial introduction of its DigiLum™ photodynamic therapy (PDT) product as an adjuvant treatment following lung cancer tumor resection.
"We are pleased to have a seasoned healthcare industry executive leading Lumeda into its next phase," said Trevor MacDougall and Paul Sanders, the company founders. "Sandy's vision for and expertise in launching new medical technologies will bring this important lung cancer therapy to the market. He brings significant experience and a network of industry contacts that will help Lumeda develop the key relationships with medical thought leaders and commercial partners critically needed to accelerate the introduction of this novel technology to the clinic, where it promises to reduce the risk of recurrence and improve patient outcomes."
Mr. Zinke has over 20 years of global healthcare industry experience with innovative companies including Boston Scientific, Cynosure/Hologic and CDx Diagnostics. Most recently, he was Vice President of Marketing & Business Development with CDx Diagnostics, known for an advanced diagnostic platform used to preempt cancer based on AI-enabled tissue analysis and 3D imaging. Over the last 10 years he has led teams that have developed and commercialized more than a dozen products and programs.
"I am excited and honored to be joining the Lumeda team comprised of experienced engineers and entrepreneurs with a track record of developing practical solutions to technical challenges across several industries," said Zinke.
Mr. Zinke's arrival augments the Lumeda management team with medical product commercialization and industry experience that complements the team's strengths in engineering, operations and business development.
About Lumeda:
Lumeda is advancing PDT to treat NSCLC and other thoracic malignancies. The company applies advanced photonics and proprietary software to automate and digitize PDT light delivery to improve PDT efficacy, ease of use and treatment planning. The multidisciplinary Lumeda team has decades of experience in the photonics industry, with expertise in systems engineering and commercialization of new technology. Lumeda is committed to pioneering the advancement and utility of PDT for improved patient outcomes. For more information, please visit lumedainc.com.
SOURCE Lumeda
Share this article